Navigation Links
Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
Date:10/29/2010

PRINCETON, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Covance Inc (NYSE: CVD) today announced that it has closed its transactions with sanofi-aventis to become its R&D partner over the next 10 years and to purchase sanofi-aventis' Porcheville, France and Alnwick, United Kingdom sites.  Covance has assumed control of the Porcheville and Alnwick sites and all sanofi-aventis employees transferred on that date at both facilities are now Covance employees.  The transaction, first announced on September 30, is expected to generate estimated revenues ranging from $1.2 billion to $2.2 billion over the course of the agreement.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
2. Covance Board Authorizes $250 Million Stock Buyback
3. Covance to Present at Morgan Stanley Global Healthcare Conference
4. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
5. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
6. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
7. Covance To Present At The 20th Annual Global Healthcare Services Conference
8. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
9. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
11. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... WARSAW, Ind. , Sept. 7, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Annual Global Healthcare Conference at the Grand Hyatt hotel ... September 11, 2017 at 11:40 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... International Water Advocate Sharon Kleyne ... Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica sponsored ... a once-every-four-years series of events to a personal, daily Health Olympics. “Wouldn’t it ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bobbie Horowitz was hardly ... and multiple health issues. As a cabaret and theater producer, Horowitz would manage to ... source of transportation in New York City, so she had to take a cab ...
(Date:9/25/2017)... ... , ... METTLER TOLEDO is pleased to host the 3rd Annual Metrology ... symposium will feature speakers from North American National Measurement Institutes (NMI) with a purpose ... planning for the future of the modern lab. , The event is not just ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... research, today announces that 30 of its domain experts will present on ... at upcoming industry conferences and webinars. Drawing on broad and deep industry ...
Breaking Medicine News(10 mins):